ASLAN Pharmaceuticals announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX. The primary endpoint, which is the percent change in Eczema Area Severity Index (EASI) score from baseline to week 16, was statistically significant when compared to placebo (p=0.0059), even though the interim analysis was not powered for statistical significance due to the sample size. ASLAN announced positive results from the Phase 2b TREK-AD study of eblasakIMab in moderate-to- severe biologic-naive AD patients in July 2023, and is currently investigating eblasakimab In dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.425 USD | +1.24% | -4.94% | -18.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.60% | 9.5M | |
+3.23% | 108B | |
+11.19% | 104B | |
+1.28% | 22.33B | |
-12.82% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.61% | 17.64B | |
+4.33% | 14.05B | |
+34.85% | 12.51B |
- Stock Market
- Equities
- ASLN Stock
- News ASLAN Pharmaceuticals Limited
- ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients